Abstract
Objectives The UK government is consulting on banning disposable e-cigarettes. This study aimed to describe trends in disposable e-cigarette use among adults in Great Britain since 2021 and establish who would currently be affected by a ban on disposables.
Study design Nationally-representative monthly cross-sectional survey.
Methods We analysed data from 69,973 adults surveyed between January-2021 and August-2023. We estimated monthly time trends in the weighted prevalence of current disposable e-cigarette use among adults and by sociodemographic characteristics and smoking status.
Results From January-2021 to August-2023, the prevalence of disposable e-cigarette use grew from 0.1% to 4.9%. This rise was observed across all population subgroups but was most pronounced among younger adults (e.g., reaching 15.9% of 18-year-olds compared with 1.3% of 65-year-olds), those who currently smoke (16.3%), and those who stopped smoking in the past year (18.2%). Use among never smokers remained relatively rare (1.5%), except among 18-24-year-olds (7.1%). Use was significantly higher in England than Wales or Scotland (5.3% vs. 2.0% and 2.8%) and among less (vs. more) advantaged social grades (6.1% vs. 4.0%), those with (vs. without) children (6.4% vs. 4.4%), and those with (vs. without) a history of mental health conditions (9.3% vs. 3.1%).
Conclusions A ban on disposable e-cigarettes would currently affect one in 20 adults in Great Britain (approximately 2.6 million people). The impact would be greatest on young people, including the 316,000 18-24 year-olds who currently use disposables but who have never regularly smoked tobacco, which may discourage uptake of vaping in this group. However, a ban would also affect 1.1 million people who currently smoke and a further 744,000 who previously smoked. It would also have a disproportionate impact on disadvantaged groups that have higher rates of smoking and typically find it harder to quit.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Funding Statement
This work was supported by CRUK (PRCRPG-Nov21\100002) and UK Prevention Research Partnership (MR/S037519/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymized when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available on Open Science Framework (https://osf.io/uwfd3/).
